Development of CAR T Cell Therapy in Children-A Comprehensive Overview
CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CA...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical medicine 2022-04, Vol.11 (8), p.2158 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 8 |
| container_start_page | 2158 |
| container_title | Journal of clinical medicine |
| container_volume | 11 |
| creator | Boettcher, Michael Joechner, Alexander Li, Ziduo Yang, Sile Fiona Schlegel, Patrick |
| description | CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CAR T cell therapy has been approved by the Food and Drug administration and the European Medicines Agency for pediatric and young adult patients first. Commonly, novel therapies are developed for adult patients and then adapted for pediatric use, due to regulatory and commercial reasons. Both strategic and biological factors have supported the success of CAR T cell therapy in children. Since there is an urgent need for more potent and specific therapies in childhood malignancies, efforts should also include the development of CAR therapeutics and expand applicability by introducing new technologies. Basic aspects, the evolution and the drawbacks of childhood CAR T cell therapy are discussed as along with the latest clinically relevant information. |
| doi_str_mv | 10.3390/jcm11082158 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9024694</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2652975441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c409t-a30f9116b8b8beab1af79e478156fc8e80e86d2630b91137246f27814b5bd8753</originalsourceid><addsrcrecordid>eNpdkc1LxDAQxYMoKurJuwS8CFLNZ5tehKW6KiwsyHoOaTt1u7RNTXYr_vemuMrq5DCB-fHmDQ-hc0puOE_J7apoKSWKUan20DEjSRIRrvj-zv8InXm_IqGUEowmh-iISyFjJskxmt7DAI3tW-jW2FY4m7zgBc6gafBiCc70n7jucLasm9JBF01wZtvewRI6Xw-A5wO4oYaPU3RQmcbD2bafoNfpwyJ7imbzx-dsMosKQdJ1ZDipUkrjXIUHJqemSlIQiaIyrgoFioCKSxZzkgeMJ0zEFQtTkcu8VInkJ-juW7ff5C2URXDtTKN7V7fGfWprav130tVL_WYHnZKglYogcLUVcPZ9A36t29oX4VzTgd14zWIpxo1sRC__oSu7cV04b6RYmkghaKCuv6nCWe8dVL9mKNFjRHonokBf7Pr_ZX8C4V-SEYpM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2652975441</pqid></control><display><type>article</type><title>Development of CAR T Cell Therapy in Children-A Comprehensive Overview</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Boettcher, Michael ; Joechner, Alexander ; Li, Ziduo ; Yang, Sile Fiona ; Schlegel, Patrick</creator><creatorcontrib>Boettcher, Michael ; Joechner, Alexander ; Li, Ziduo ; Yang, Sile Fiona ; Schlegel, Patrick</creatorcontrib><description>CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CAR T cell therapy has been approved by the Food and Drug administration and the European Medicines Agency for pediatric and young adult patients first. Commonly, novel therapies are developed for adult patients and then adapted for pediatric use, due to regulatory and commercial reasons. Both strategic and biological factors have supported the success of CAR T cell therapy in children. Since there is an urgent need for more potent and specific therapies in childhood malignancies, efforts should also include the development of CAR therapeutics and expand applicability by introducing new technologies. Basic aspects, the evolution and the drawbacks of childhood CAR T cell therapy are discussed as along with the latest clinically relevant information.</description><identifier>ISSN: 2077-0383</identifier><identifier>EISSN: 2077-0383</identifier><identifier>DOI: 10.3390/jcm11082158</identifier><identifier>PMID: 35456250</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antigens ; Cancer ; Chemotherapy ; Clinical medicine ; Clinical trials ; Cytokines ; FDA approval ; Gene expression ; Immunotherapy ; Leukemia ; Lymphocytes ; Lymphoma ; Medical prognosis ; Pediatrics ; Review ; Senescence ; Signal transduction ; Success ; T cell receptors ; Young adults</subject><ispartof>Journal of clinical medicine, 2022-04, Vol.11 (8), p.2158</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c409t-a30f9116b8b8beab1af79e478156fc8e80e86d2630b91137246f27814b5bd8753</citedby><cites>FETCH-LOGICAL-c409t-a30f9116b8b8beab1af79e478156fc8e80e86d2630b91137246f27814b5bd8753</cites><orcidid>0000-0003-4972-9866</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024694/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024694/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27922,27923,53789,53791</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35456250$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boettcher, Michael</creatorcontrib><creatorcontrib>Joechner, Alexander</creatorcontrib><creatorcontrib>Li, Ziduo</creatorcontrib><creatorcontrib>Yang, Sile Fiona</creatorcontrib><creatorcontrib>Schlegel, Patrick</creatorcontrib><title>Development of CAR T Cell Therapy in Children-A Comprehensive Overview</title><title>Journal of clinical medicine</title><addtitle>J Clin Med</addtitle><description>CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CAR T cell therapy has been approved by the Food and Drug administration and the European Medicines Agency for pediatric and young adult patients first. Commonly, novel therapies are developed for adult patients and then adapted for pediatric use, due to regulatory and commercial reasons. Both strategic and biological factors have supported the success of CAR T cell therapy in children. Since there is an urgent need for more potent and specific therapies in childhood malignancies, efforts should also include the development of CAR therapeutics and expand applicability by introducing new technologies. Basic aspects, the evolution and the drawbacks of childhood CAR T cell therapy are discussed as along with the latest clinically relevant information.</description><subject>Antigens</subject><subject>Cancer</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>FDA approval</subject><subject>Gene expression</subject><subject>Immunotherapy</subject><subject>Leukemia</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Medical prognosis</subject><subject>Pediatrics</subject><subject>Review</subject><subject>Senescence</subject><subject>Signal transduction</subject><subject>Success</subject><subject>T cell receptors</subject><subject>Young adults</subject><issn>2077-0383</issn><issn>2077-0383</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNpdkc1LxDAQxYMoKurJuwS8CFLNZ5tehKW6KiwsyHoOaTt1u7RNTXYr_vemuMrq5DCB-fHmDQ-hc0puOE_J7apoKSWKUan20DEjSRIRrvj-zv8InXm_IqGUEowmh-iISyFjJskxmt7DAI3tW-jW2FY4m7zgBc6gafBiCc70n7jucLasm9JBF01wZtvewRI6Xw-A5wO4oYaPU3RQmcbD2bafoNfpwyJ7imbzx-dsMosKQdJ1ZDipUkrjXIUHJqemSlIQiaIyrgoFioCKSxZzkgeMJ0zEFQtTkcu8VInkJ-juW7ff5C2URXDtTKN7V7fGfWprav130tVL_WYHnZKglYogcLUVcPZ9A36t29oX4VzTgd14zWIpxo1sRC__oSu7cV04b6RYmkghaKCuv6nCWe8dVL9mKNFjRHonokBf7Pr_ZX8C4V-SEYpM</recordid><startdate>20220412</startdate><enddate>20220412</enddate><creator>Boettcher, Michael</creator><creator>Joechner, Alexander</creator><creator>Li, Ziduo</creator><creator>Yang, Sile Fiona</creator><creator>Schlegel, Patrick</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-4972-9866</orcidid></search><sort><creationdate>20220412</creationdate><title>Development of CAR T Cell Therapy in Children-A Comprehensive Overview</title><author>Boettcher, Michael ; Joechner, Alexander ; Li, Ziduo ; Yang, Sile Fiona ; Schlegel, Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c409t-a30f9116b8b8beab1af79e478156fc8e80e86d2630b91137246f27814b5bd8753</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Cancer</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>FDA approval</topic><topic>Gene expression</topic><topic>Immunotherapy</topic><topic>Leukemia</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Medical prognosis</topic><topic>Pediatrics</topic><topic>Review</topic><topic>Senescence</topic><topic>Signal transduction</topic><topic>Success</topic><topic>T cell receptors</topic><topic>Young adults</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boettcher, Michael</creatorcontrib><creatorcontrib>Joechner, Alexander</creatorcontrib><creatorcontrib>Li, Ziduo</creatorcontrib><creatorcontrib>Yang, Sile Fiona</creatorcontrib><creatorcontrib>Schlegel, Patrick</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boettcher, Michael</au><au>Joechner, Alexander</au><au>Li, Ziduo</au><au>Yang, Sile Fiona</au><au>Schlegel, Patrick</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of CAR T Cell Therapy in Children-A Comprehensive Overview</atitle><jtitle>Journal of clinical medicine</jtitle><addtitle>J Clin Med</addtitle><date>2022-04-12</date><risdate>2022</risdate><volume>11</volume><issue>8</issue><spage>2158</spage><pages>2158-</pages><issn>2077-0383</issn><eissn>2077-0383</eissn><abstract>CAR T cell therapy has revolutionized immunotherapy in the last decade with the successful establishment of chimeric antigen receptor (CAR)-expressing cellular therapies as an alternative treatment in relapsed and refractory CD19-positive leukemias and lymphomas. There are fundamental reasons why CAR T cell therapy has been approved by the Food and Drug administration and the European Medicines Agency for pediatric and young adult patients first. Commonly, novel therapies are developed for adult patients and then adapted for pediatric use, due to regulatory and commercial reasons. Both strategic and biological factors have supported the success of CAR T cell therapy in children. Since there is an urgent need for more potent and specific therapies in childhood malignancies, efforts should also include the development of CAR therapeutics and expand applicability by introducing new technologies. Basic aspects, the evolution and the drawbacks of childhood CAR T cell therapy are discussed as along with the latest clinically relevant information.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>35456250</pmid><doi>10.3390/jcm11082158</doi><orcidid>https://orcid.org/0000-0003-4972-9866</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2077-0383 |
| ispartof | Journal of clinical medicine, 2022-04, Vol.11 (8), p.2158 |
| issn | 2077-0383 2077-0383 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9024694 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Antigens Cancer Chemotherapy Clinical medicine Clinical trials Cytokines FDA approval Gene expression Immunotherapy Leukemia Lymphocytes Lymphoma Medical prognosis Pediatrics Review Senescence Signal transduction Success T cell receptors Young adults |
| title | Development of CAR T Cell Therapy in Children-A Comprehensive Overview |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T08%3A40%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20CAR%20T%20Cell%20Therapy%20in%20Children-A%20Comprehensive%20Overview&rft.jtitle=Journal%20of%20clinical%20medicine&rft.au=Boettcher,%20Michael&rft.date=2022-04-12&rft.volume=11&rft.issue=8&rft.spage=2158&rft.pages=2158-&rft.issn=2077-0383&rft.eissn=2077-0383&rft_id=info:doi/10.3390/jcm11082158&rft_dat=%3Cproquest_pubme%3E2652975441%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2652975441&rft_id=info:pmid/35456250&rfr_iscdi=true |